← Back to Clinical Trials
Recruiting NCT06319560

NCT06319560 Hydroxychloroquine in Type 2 Diabetes During Pregnancy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06319560
Status Recruiting
Phase
Sponsor National University of Malaysia
Condition Diabetes in Pregnancy
Study Type INTERVENTIONAL
Enrollment 56 participants
Start Date 2024-03-24
Primary Completion 2026-06-01

Eligibility & Interventions

Sex Female only
Min Age 20 Years
Max Age 45 Years
Study Type INTERVENTIONAL
Interventions
Hydroxychloroquine Oral Tablet

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 56 participants in total. It began in 2024-03-24 with a primary completion date of 2026-06-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to compare the use of hydroxychloroquine as an adjunct to the current treatment of pregnant women with Type 2 diabetes mellitus. The main questions it aims to answer are: * Does hydroxychloroquine improve the pregnancy outcomes in women with type 2 diabetes during pregnancy? * Does hydroxychloroquine improve the inflammatory markers in women with type 2 diabetes during pregnancy? Participants will be randomised into the intervention and control group. The control group will be on standard treatment where as the intervention group will receive hydroxychloroquine as an adjunct of standard treatment

Eligibility Criteria

Inclusion Criteria: * Singleton * Pregnant women with a confirmed diagnosis of type 2 Diabetes Mellitus Exclusion Criteria: * autoimmune disease such as Systemic Lupus Erythematosus or rheumatic disease * chronic kidney disease * fetal anomaly * women on steroid therapy * diabetic retinopathy * known thalassaemia or thalassaemia carrier

Contact & Investigator

Central Contact

Rahana Abdul Rahman, MD

✉ drrahana@ukm.edu.my

📞 039145

Principal Investigator

Rahana Abd Rahman

PRINCIPAL INVESTIGATOR

UKM

Frequently Asked Questions

Who can join the NCT06319560 clinical trial?

This trial is open to female participants only, aged 20 Years or older, up to 45 Years, studying Diabetes in Pregnancy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06319560 currently recruiting?

Yes, NCT06319560 is actively recruiting participants. Contact the research team at drrahana@ukm.edu.my for enrollment information.

Where is the NCT06319560 trial being conducted?

This trial is being conducted at Cheras, Malaysia.

Who is sponsoring the NCT06319560 clinical trial?

NCT06319560 is sponsored by National University of Malaysia. The principal investigator is Rahana Abd Rahman at UKM. The trial plans to enroll 56 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology